We describe the case of a 25-year-old athlete experiencing syncope during a 5-km running race. A thorough diagnostic workup reasonably excluded a cardiac disorder as the cause of syncope. The characterization of this episode of syncope as noncardiac appears to contradict the common belief that syncope during exercise has always a cardiac origin. Following a detailed history taking, it was revealed that the symptoms of the athlete started after a 180° turn of the route. This situation represents a setting relevant to a runner who stops suddenly after reaching the finish line and soon after experiences noncardiac syncope due to the abrupt cessation of muscle pump function of the lower limbs. Although the symptoms of the athlete in this report occurred during running, implying at a first glance the diagnosis of syncope occurring during exercise, a more detailed analysis of the circumstances indicated that these symptoms were in essence presenting after exercise from a pathophysiological view. The distinction between syncope occurring during and after exercise may be challenging enough for athletic activities involving a sudden stop of the running activity, such as for running races with sudden inversion of the route and sports characterized by rapid “starts and stops.”

Keywords:
Athletes, Syncope after exercise, Cardiac disorders, Running
1.
Moya A, Sutton R, Ammirati F, Blanc JJ, Brignole M, Dahm JB, Deharo JC, et al: Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J 2009;30:2631-2671.
2.
Colivicchi F, Ammirati F, Biffi A, Verdile L, Pelliccia A, Santini M: Exercise-related syncope in young competitive athletes without evidence of structural heart disease. Clinical presentation and long-term outcome. Eur Heart J 2002;23:1125-1130.
3.
Colivicchi F, Ammirati F, Santini M: Epidemiology and prognostic implications of syncope in young competing athletes. Eur Heart J 2004;25:1749-1753.
4.
Holtzhausen LM, Noakes TD: The prevalence and significance of post-exercise (postural) hypotension in ultramarathon runners. Med Sci Sports Exerc 1995;27:1595-1601.
5.
Armstrong LE, Casa DJ, Millard-Stafford M, Moran DS, Pyne SW, Roberts WO: American College of Sports Medicine position stand. Exertional heat illness during training and competition. Med Sci Sports Exerc 2007;39:556-572.
6.
Hew-Butler T, Ayus JC, Kipps C, Maughan RJ, Mettler S, Meeuwisse WH, Page AJ, et al: Statement of the Second International Exercise-Associated Hyponatremia Consensus Development Conference, New Zealand, 2007. Clin J Sport Med 2008;18:111-121.
7.
Almond CS, Shin AY, Fortescue EB: Hyponatremia among runners in the Boston Marathon. N Engl J Med 2005;352:1550-1556.
8.
Smith GD, Watson LP, Pavitt DV, Mathias CJ: Abnormal cardiovascular and catecholamine responses to supine exercise in human subjects with sympathetic dysfunction. J Physiol 1995;484:255-265.
9.
Thompson PD: Tilt table testing in the evaluation and management of athletes with recurrent exercise-induced syncope. Med Sci Sports Exerc 1993;25:883.
10.
Holtzhausen LM, Noakes TD, Kroning B, de Klerk M, Roberts M, Emsley R: Clinical and biochemical characteristics of collapsed ultra-marathon runners. Med Sci Sports Exerc 1994;26:1095-1101.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.